Merck wins first PD1 sprint in US

  • Published 2014 in Nature Reviews Drug Discovery

Abstract

treat patients’ symptoms (Bel, E. H. et al. N. Engl. J. Med, 8 Sep 2014). A regulatory filing is now expected by the end of the year. Yet, a linked editorial notes that although the drug was safe and effective, “these studies do not suggest that all patients with uncontrolled asthma who have peripheral blood eosinophilia will require an expensive anti-IL-5 therapy for clinical benefit”. Parameswaran Nair, of McMaster University, Canada, points out that the exacerbation rate in the larger trial fell by over 50% even with just the placebo, which suggests that many patients may benefit just from improved adherence to available drug regimens and good clinical practice (Nair, P. N. Engl. J. Med. 8 Sep 2014). AstraZeneca’s IL‐5 receptor (IL‐5R)‐specific benralizumab and Teva’s IL‐5‐specific reslizumab are also in Phase III trials for asthma. AstraZeneca and GSK have also both moved their drugs into Phase III for chronic obstructive pulmonary disease (COPD). AstraZeneca Illuminating interleukin‐5 data

DOI: 10.1038/nrd4458

Cite this paper

@article{2014MerckWF, title={Merck wins first PD1 sprint in US}, author={}, journal={Nature Reviews Drug Discovery}, year={2014}, volume={13}, pages={715-715} }